| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S18251 R76877 |
Suarez (Controls unexposed, discontinuers), 2022 | Intellectual disability - ≥ 2 dates with ICD-9 Dx 317, 318.x, 319 - At ≥ 2 years of age | 2nd and/or 3rd trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes Monotherapy: no or not specified Unexposed sick: recent illness/treatment (during or juste before pregnancy or treatment stopped in view of pregnancy) | 0.73 [0.30;1.76] | 47/18,357 13/5,638 | 60 | 18,357 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18252 R76878 |
Suarez (Controls unexposed, general pop), 2022 | Intellectual disability - ≥ 2 dates with ICD-9 Dx 317, 318.x, 319 - At ≥ 2 years of age | 2nd and/or 3rd trimester | retrospective cohort (claims database) | unexposed (general population or NOS) excluded | Adjustment: Yes Monotherapy: no or not specified |
0.96 [0.68;1.36] excluded (control group) |
47/18,385 2,800/1,790,067 | 2,847 | 18,385 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S10004 R53804 |
Ames, 2021 | Developmental delays or disorders (identified from clinical or educational settings) and with score <11 on the SCQ or score >=11 but did not meet study criteria for ASD after the in-person assessment (presence or absence of co-occurring ID defined by MSEL composite standard scores <=70) (Age NOS). | 3 months (or more) before pregnancy or during pregnancy excluded | case control | unexposed, disease free | Adjustment: No Monotherapy: no or not specified |
1.65 [0.96;2.84] C excluded (exposition period) |
36/57 1,714/3,364 | 1,750 | 57 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8015 R53805 |
Nulman (Controls exposed to TCA), 2002 | Global IQ with the McCarthy Scales of Children’s Abilities at 30 and 71 months of age | throughout pregnancy | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No extrapolated (cont. endpoint) Monotherapy: SSRI only |
3.35 [0.60;18.67] excluded (control group) |
-/6 -/18 | - | 6 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8016 R53806 |
Nulman (Controls unexposed, disease free), 2002 | Global IQ with the McCarthy Scales of Children’s Abilities at 30 and 71 months of age | throughout pregnancy | prospective cohort | unexposed, disease free | Adjustment: No extrapolated (cont. endpoint) Monotherapy: SSRI only | 3.79 [0.66;21.98] | -/6 -/16 | - | 6 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 2 studies | 1.39 [0.29;6.70] | 60 | 18,363 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, discontinuers; 2: Controls unexposed, disease free;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 8015, 18252